healthcare industry 2016 - mobile area chamber of...
TRANSCRIPT
HealthcareIndustry 2016
FactsandFiguresforBaden-Württemberg
BIOPROBaden-WürttembergGmbH
presented by:
Prof.Dr.RalfKindervater
CEOof BIOPROBaden-WürttembergGmbH&
Honorary ProfessoratKarlsruheInstituteof Technology(KIT)
BIOPRO Baden-Württemberg GmbH
Strong interaction with: ü State Ministries,ü Federal Ministriesü Regional Clustersü Universitiesü R&D-organizationsü Companies
Innovation and public relation agency (started 2003)
Non for profit, state owned organization:
100% ownership by the State of Baden-Württemberg
- 15 employees- Activity fields: Support for healtcare industry
(Pharma, Medtech, Biotech)- Assembly of a biobased economy in Baden-
Württemberg
© BIOPRO Baden-Württemberg | The figures are from 2014 and were calculated by the Baden-Württemberg Statistics Office based on data held in the BIOPRO company databse.
TheHealthcareIndustryFiguresforBaden-Württemberg
The figures only include companies that are involved in research, development and/or productionin Baden-Württemberg.
Gross value added, GVA: total value of all goods and services produced that are not used within the productionprocess, less intermediate expenditure. The GVA is the basis for the calculation of gross domestic product.
13.8 billion euros gross value added// including production, distribution and wholesale
2.2% growth p.a.// between 2004 and 2014, in real terms
Data collection: WifOR | issued by BIOPRO Baden-Württemberg
Financial leverage 1+1 // 1 € GVA in the healthcare industry generates another euroof GVA in other sectors of the economy
€
%
Theeconomic footprint of the healthcare industry inBWKeyfindings for2014
11.1% proportion of total exports// in Baden-Württemberg in 2014
Competing powerof the healthcare industry inBWKeyfindings for2014
€
%
20.1 billion euros exports// in 2014
6.7% increase in exports p.a.// between 2004 and 2014
Data collection: WifOR | issued by BIOPRO Baden-Württemberg
SME Large companies1-249 employees 250 + employees
6,8 Mrd. Euro 7,0 Mrd. Euro
110.800 63.600
Companystructure of the healtcare industry inBaden-Württemberg|Keyfindings for 2014
€ €
Data collection: WifOR | issued by BIOPRO Baden-Württemberg
SMEs and Large Companies are the two strong pillarsof the healthcare industry in Baden-Württemberg.
Medical technology sector*818 companies47,094 employees12.1 billion euros taxable turnover
MedicalTechnology2016Keyfindings for2014
* The figures only include companies thatare involved in research, developmentand/or production in Baden-Württemberg.
© BIOPRO Baden-Württemberg | The figures are from 2014 and were calculated by theBaden-Württemberg Statistics Office based on data held in the BIOPRO company databse.
SMEsand largecompanies are the two strongpillars of the healthcare industry inBaden-Württemberg.Themedical technology index shows revenue growth inthe Baden-Württembergmedical technology sectorover recent years.Taxable revenues rose by 28percent between 2007and 2014.
MedicalTechnology2016Keyfindings for2014
€
* Companies may have several flieds of activity
MedicalTechnology2016Keyfindings for2014
Baden-Württembergcompanies produce differentcategories of medical technology prducts,mostlysurgical instruments.
Biotechnology sector156 biotech companies18,680 employees5.0 billion euros taxable turnover
Pharmaceutical industry80 pharma companies18,150 employees6.2 billion euro taxable turnover
Biotechand Pharmaceutical Industry 2016Keyfindings for2014
© BIOPRO Baden-Württemberg | The figures are from 2014 and were calculated by theBaden-Württemberg Statistics Office based on data held in the BIOPRO company databse.
The figures only include companies thatare involved in research, developmentand/or production in Baden-Württemberg.
© BIOPRO Baden-Württemberg GmbH
* Companies may have several fields of activity
Fieldsof activity of biotech and pharmaceutical companiesKeyfindings for2014
Innovationcapacity of the healthcare industry inBWKeyfindings for2014
0 2 4 6 8 10 12 14 16
1990
1995
2000
2005
2010
2015
2016
Numberofcompanies
Yearoffou
ndation
Baden-Württembergis afirst-classlocation for biotech companies.Fourteen biotechnology companieswere founded between 2015and 2016.
© BIOPRO Baden-Württemberg GmbH
Succes Story|Apogenix |AbbVie
Apogenix is a Heidelberg-based biopharmaceutical company founded in 2005.
Developing next generation immuno-oncology therapeutics.
à ABBV621 is a novel, second generation TRAIL receptor agonist consisting ofsix receptor binding domains of TRAIL fused to the Fc domain of a human IgG1antibody.à This novel protein was engineered by Apogenix employing its proprietaryHERA technology platform (hexavalent receptor agonists).à A clinical phase I study with patients sufering solid tumors, NHL or AML hasbeen launched in April 2017 by ist partner AbbVie.
Curetis was founded in 2007 in Holzgerlingen. An IPO was placed in 2015 at Euronext, Amsterdam.
More and more bacteria are developing resistance to multiple antimicrobial drugs.
à Curetis developed a diagnotsic system for fast and reliable detection ofpathogens and antimicrobal resistances.
à The system uses different cartridges to identify various pathogens and antibioticresistance markers for the simple and rapid identification of severe infectionssuch as pneumonia, tissue and bloos infctions.
Succes Story|Curetis |Early-diagnosis systems
Succes Story|CureVac |Vaccines made inGermany
CureVac is a Tübingen-based biopharmaceutical company founded in 2000.
The World Health Organization states that vaccines are the mosteffective and low-cost strategy to fight infectious diseases.
à CureVac developes RNA-based technologies in which the body receives
specific information coded in RNA. This information is used to produce its own,
custom-tailored protein as medicine. © CureVac
à CureVac focuses on the development of Cancer Immunotherapies,
Prophylactic Vaccines and Adjvants for Vaccines. © CureVac
Succes Story|CureVac‘sPipeline|Examples
Succes Story|Biocopy |Start-up
Biocopy is a spin out of the University of Freiburg and was founded in 2016.
Time is crucial in vaccine development.
à BioCopy developed a (patented) biomolecular copier, able to copy DNA ofpathogens in to a microarray. The DNA is then converted into a proteinmicroarray, displaying all pathogeneic proteins.
à Blood from a survivor – containing protecting antibodies – is added used toidentify immunogeneic proteins.
à The potential vaccine candidate is found within ‚48 hours‘.
Succes Story|FundaMental Pharma|Start-up
FundaMental Pharma is a spin-out of the University of Heidelberg, founded 2016.
A nasal spray for treating neurodegenerative diseases.
à Development of a nasal spray that stabilizes the dendrites of the nerve cells, thus reducing nerve damage and brain function losses following a stroke.
à The application via a nasal spray that is non-invasive spares the patientundue discomfort.
à The method is highly efficient as the drugs enter directly the brain by wayof the olfactory nerve in the nasal cavity, by-passing the blood-brain-barrier.
Succes Story|Mireca Medicines GmbH|Start-up
Mireca Medicines is a spin out of the University of Tübingen and was founded in 2017.
Developing treatment for hereditary retinal degeneration.
à Regulation of cGMP is disturbed in many different types of hederitaryphotoreceptor degeneration (e.g. Retinitis pigmentosa and Achromatopsia).
à Novel cGMP regulating substances combined with drug delivery techniquesable to cross the blood-brain-barrier in order to reach the photoreceptors will be developed.
à Mireca originated from an EU-funded project called DRUGSFORD.
Succes Story|Towards individualized cancer medicine
The National Center for Tumour Diseases in Heidelberg and partners.
Comprehensive genome analyses of cancer cells have shown thateach tumour and cancer patient are unique and need to be treatedindividually.
à NCT aims to offer cancer patients analyses of their individual cancergenomes to be used as the basis for personalized recommendations fortreatments.
à The initiative has been made possible by generous support from the Dietmar Hopp foundation.
Current innovation and support topics handled by BIOPRO:
• Digitalization of production and products in healthcare industry• Industry 4.0 (industrial internet)• E-health• Telemedicine• Assisted ambient living systems
• Personalization of products• Individual implants• Regenerative medicine (e.g. tissue implants, printed organs)• Compagnion diagnostics• Patient stratification in cancer and neurodegenrative diseases
• Miniaturization of products• Lab on chip systems• Intelligent implants• Micro systems technology for various medical tasks
• Automation of production• Automated cell culture fabrication• Automated cell separation and handling (e.g. printing)• Automation concepts for complex drug development tasks
Thank you for your attention !!!
Furtherinformation andcontact:
BIOPROBaden-WürttembergGmbHBreitscheidstraße10,70174Stuttgart
Phone0xx49711– 21818500Faxxx49711– 21818502E-Mail:[email protected]@GesundheitBW
BIOPROBaden-WürttembergGmbHPoolingcompetencies – pushing innovations